Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

KBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

The financing was co-led by Advantech Capital and SDIC Venture Capital. Source: BioSpace

Continue ReadingKBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly

3 Biotechs That Could Outperform in 2018

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

A look at why investors should stock up on Amgen, Celldex Therapeutics, and Novavax soon. Source: BioSpace

Continue Reading3 Biotechs That Could Outperform in 2018

BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossifica…

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

FOP is a very rare disease that affects approximately 1 in 2 million people worldwide. Source: BioSpace

Continue ReadingBioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossifica…

FDA Denies Allergan Petition for Higher Bar for Restasis Copies

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:Drug Industry Daily

The FDA denied a request from Allergan to reject any ANDAs referencing Restasis unless the applicant proves bioequivalence through clinical endpoints. Source: Drug Industry Daily

Continue ReadingFDA Denies Allergan Petition for Higher Bar for Restasis Copies

Saint Regis Tribe Seeks Information on PTAB Panel

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:Drug Industry Daily

The Native American tribe that entered a controversial patent deal with Allergan is questioning the impartiality of the Patent Trial and Appeals Board judges charged with reviewing the arrangement. Source:…

Continue ReadingSaint Regis Tribe Seeks Information on PTAB Panel

OPDP Enforcement Letters in 2017 Hit Record Low

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:Drug Industry Daily

The FDA’s Office of Prescription Drug Promotion issued just three warning letters and one untitled letter in calendar year 2017 — a record low and down from a high of…

Continue ReadingOPDP Enforcement Letters in 2017 Hit Record Low

Bay Area's ChemoCentryx Gets Up to $100M in New Capital Commitments

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

The additional capital is expected to provide funding to advance avacopan through topline data from the Phase III ADVOCATE trial as well as potential registration filings in the U.S. and…

Continue ReadingBay Area's ChemoCentryx Gets Up to $100M in New Capital Commitments

What You Need to Know About Prelude Fertility

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

Prelude Fertility was founded in late 2016 by successful startup entrepreneur Martin Varsavsky with a $200M investment. Source: BioSpace

Continue ReadingWhat You Need to Know About Prelude Fertility

German Biotech BioNTech Locks in $270M Series A

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

The Company previously completed a seed round fundraising in 2008 concurrent with its founding. Source: BioSpace

Continue ReadingGerman Biotech BioNTech Locks in $270M Series A

Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

Pfizer will use Arvinas' proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Source: BioSpace

Continue ReadingPfizer, Arvinas Forge $830M Protein Degradation R&D Deal
  • Go to the previous page
  • 1
  • …
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.